Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer

被引：1

作者：

Ko, R. ^{[1
]}

Oizumi, S. ^{[2
]}

Mizugaki, H. ^{[3
]}

Fujita, Y. ^{[2
]}

Harada, T. ^{[4
]}

Takashina, T. ^{[5
]}

Igawa, S. ^{[6
]}

Watanabe, K. ^{[7
]}

Hotta, T. ^{[8
]}

Minemura, H. ^{[9
]}

Saeki, S. ^{[10
]}

Yagishita, S. ^{[11
]}

Hamada, A. ^{[11
]}

机构：

[1] Juntendo Univ, Grad Sch Med, Resp Med, Tokyo, Japan

[2] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan

[4] Jcho Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[5] Iwamizawa Municipal Gen Hosp, Iwamizawa, Japan

[6] Kitasato Univ, Sch Med, Resp Med, Sagamihara, Kanagawa, Japan

[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[8] Shimane Univ, Fac Med, Izumo, Shimane, Japan

[9] Fukushima Med Univ, Pulm Med, Fukushima, Japan

[10] Kumamoto Univ, Kumamoto, Japan

[11] Natl Canc Ctr, Res Inst, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

Afatinib; Adverse events; Elderly patients;

D O I：

10.1016/j.jtho.2019.08.1187

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.14-36

引用

页码：S568 / S568

页数：1

共 50 条

[21] COMPARATIVE SAFETY PROFILE OF AFATINIB IN ASIAN AND NON-ASIAN PATIENTS WITH EGFR MUTATION-POSITIVE (EGFR M plus ) NON-SMALL CELL LUNG CANCER (NSCLC)
Sequist, Lecia V.
Yang, James C.
Yamamoto, Nobuyuki
O'Byrne, Kenneth
Schuler, Martin
Mok, Tony
Geater, Sarayut Lucien
Massey, Daniel
Wind, Sven
O'Brien, Dennis
Lorence, Robert
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1197 - S1197
[22] Radiation therapy for stage I-II non-small cell lung cancer in patients aged 75 years and older
Furuta, M
Hayakawa, K
Katano, S
Saito, Y
Nakayama, Y
Takahashi, T
Imai, R
Ebara, T
Mitsuhashi, N
Niibe, H
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1996, 26 (02) : 95 - 98
[23] Afatinib in EGFR TKI-Naive Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
Passaro, Antonio
de Marinis, Filippo
Tu, Hai-Yan
Laktionov, Konstantin K.
Feng, Jifeng
Poltoratskiy, Artem
Zhao, Jun
Tan, Eng Huat
Gottfried, Maya
Lee, Victor
Kowalski, Dariusz
Yang, Cheng Ta
Srinivasa, B. J.
Clementi, Laura
Jalikop, Tejaswini
Huang, Dennis Chin Lun
Cseh, Agnieszka
Park, Keunchil
Wu, Yi-Long
FRONTIERS IN ONCOLOGY, 2021, 11
[24] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Imai, Hisao
Wasamoto, Satoshi
Yamaguchi, Ou
Suzuki, Kensuke
Sugiyama, Tomohide
Uchino, Junji
Minemura, Hiroyuki
Osaki, Takashi
Ishii, Hisashi
Umeda, Yukihiro
Mori, Keita
Kotake, Mie
Kagamu, Hiroshi
Morozumi, Nobutoshi
Taniguchi, Hirokazu
Kasai, Takashi
Minato, Koichi
Kaira, Kyoichi
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 457 - 466
[25] Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Endo, Satoshi
Imai, Hisao
Mouri, Atsuto
Tsukamoto, Kasumi
Masaki, Kenji
Hashimoto, Kosuke
Miura, Yu
Shiono, Ayako
Yamaguchi, Ou
Nakagawa, Junichi
Kaira, Kyoichi
Kobayashi, Kunihiko
Kagamu, Hiroshi
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (01)
[26] Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer
Sugiyama, T.
Imai, H.
Wasamoto, S.
Yamaguchi, O.
Suzuki, K.
Uchino, J.
Minemura, H.
Osaki, T.
Ishii, T.
Umeda, Y.
Taniguchi, H.
Kasai, T.
Minato, K.
Kaira, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S453 - S453
[27] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Hisao Imai
Satoshi Wasamoto
Ou Yamaguchi
Kensuke Suzuki
Tomohide Sugiyama
Junji Uchino
Hiroyuki Minemura
Takashi Osaki
Hisashi Ishii
Yukihiro Umeda
Keita Mori
Mie Kotake
Hiroshi Kagamu
Nobutoshi Morozumi
Hirokazu Taniguchi
Takashi Kasai
Koichi Minato
Kyoichi Kaira
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 457 - 466
[28] Acquired Resistance to Afatinib in Non-Small Cell Lung Cancer with EGFR G719X Mutation
Harada, T.
Futamura, S.
Inoue, Y.
Sawada, R.
Okuda, T.
Kagawa, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S687 - S687
[29] Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older
Chen, Yuh-Min
Tsai, Chun-Ming
Fan, Wen-Chien
Shih, Jen-Fu
Liu, Shih-Hao
Wu, Chieh-Hung
Chou, Teh-Ying
Lee, Yu-Chin
Perng, Reury-Perng
Whang-Peng, Jacqueline
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) : 412 - 418
[30] Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient
Tao, Junyan
Sun, Dantong
Hou, Helei
THORACIC CANCER, 2020, 11 (09) : 2736 - 2739

← 1 2 3 4 5 →